Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Brown & Brown logoBrown & Brown BRO

Brown & Brown said commissions and fees, including profit-sharing contingent commissions, for Q1 2025 increased $148 million to $1,385 million, or 12.0%, compared with the same period in the prior year, and the Organic Revenue growth rate was 6.5%.

10-QQuarterly reportFiled Period of report Summary published (UTC)

Key points

AI summary
  1. Brown & Brown said commissions and fees, including profit-sharing contingent commissions, for Q1 2025 increased $148 million to $1,385 million, or 12.0%, compared with the same period in the prior year, and the Organic Revenue growth rate was 6.5%.

  2. The company said income before income taxes for Q1 2025 increased $63 million, or 17.3%, compared with the same period in the prior year, citing Organic Revenue growth, leveraging the expense base, net new business, lower interest expense and acquisitions completed in the past 12 months as factors.

  3. Brown & Brown said operating cash flow for Q1 2025 was $213 million, an increase of $200 million compared with $13 million in the same period in the prior year. The company cited higher operating income margins and a decrease of $120 million in income taxes paid, net of refunds, as factors for the increase.

  4. The company said it completed 13 acquisitions, including book purchases, during Q1 2025 and paid $67 million in net cash, after deducting acquisition cash. Total debt as of March 31, 2025 was $3,806 million, net of unamortized discount and issuance costs.

Key figures

Quarter ended March 31, 2025

Revenue
$1.4B
Net income
$331M
EPS
$1.15
Operating cash flow
$213M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q1 2025 Commissions and Fees Revenue Increase

Brown & Brown said commissions and fees, including profit-sharing contingent commissions, for Q1 2025 increased $148 million to $1,385 million, or 12.0%, compared with the same period in the prior year, and the Organic Revenue growth rate was 6.5%.

Source · Based on the MD&A text of the filing

Q1 Income Before Income Taxes Increase and Company Explanation

The company said income before income taxes for Q1 2025 increased $63 million, or 17.3%, compared with the same period in the prior year, citing Organic Revenue growth, leveraging the expense base, net new business, lower interest expense and acquisitions completed in the past 12 months as factors.

Source · Based on the MD&A text of the filing

Q1 Operating Cash Flow Increase

Brown & Brown said operating cash flow for Q1 2025 was $213 million, an increase of $200 million compared with $13 million in the same period in the prior year. The company cited higher operating income margins and a decrease of $120 million in income taxes paid, net of refunds, as factors for the increase.

Source · Based on the MD&A text of the filing

Q1 Acquisitions and Total Debt Balance

The company said it completed 13 acquisitions, including book purchases, during Q1 2025 and paid $67 million in net cash, after deducting acquisition cash. Total debt as of March 31, 2025 was $3,806 million, net of unamortized discount and issuance costs.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.